Kamillenblüten 'tee

Matricariae Flos, the active ingredient in Kamillenblüten 'tee, is a herbal presented as a herbal tea for oral use. It is traditionally used to support mild digestive comfort and occasional sleep disturbances in adults.

GNH USA supplies Kamillenblüten 'tee as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Kamillenblüten 'tee, containing Matricariae Flos, is used for mild, self‑limited conditions affecting the gastrointestinal, nervous and integumentary systems.

Digestive discomfort: helps soothe occasional stomach cramps and mild indigestion. Sleep disturbance: promotes relaxation that may aid occasional insomnia in adults. Skin irritation: topical or inhalation use may provide soothing effect for minor skin irritations or mild eczema.

Adverse reactions to Kamillenblüten 'tee are generally mild but should be monitored.

Common Side Effects: - Mild gastrointestinal upset, such as nausea or loose stools. - Drowsiness or increased sleepiness. - Mild skin redness when applied topically. - Headache. - Transient allergic itching.

Serious or Rare Side Effects: - Anaphylactic reaction, including difficulty breathing and swelling. - Severe skin rash or Stevens‑Johnson‑like eruption. - Hepatic enzyme elevation in susceptible individuals. - Acute bronchospasm in asthma patients. - Persistent hypotension after large inhalation exposure.

When considering Kamillenblüten 'tee, several safety points are recommended. - Pregnancy: consult a healthcare professional before use. - Allergy: avoid if known hypersensitivity to Asteraceae family plants. - Anticoagulant therapy: inform the prescriber as chamomile may potentiate bleeding risk. - Children: use only under adult supervision and appropriate dosing. - Storage at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Chamomile tea can influence the activity of several medicines; interactions are categorized by clinical relevance.

Major Interactions (Avoid): - Warfarin or other oral anticoagulants: increased bleeding risk. - Central nervous system depressants (e.g., benzodiazepines, barbiturates): additive sedation. - CYP1A2 substrates (e.g., theophylline): possible increased plasma levels.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bruising. - Antihistamines: potential enhancement of drowsiness. - Diabetes medications: possible hypoglycaemic effect, monitor glucose. - Immunosuppressants: theoretical reduction in efficacy, observe therapeutic response.